major impact
Healthcare
FDA Approves Suzetrigine (Journavx) - First New Acute Pain Drug in 20 Years
Food and Drug Administration
United States
Published Jan 30, 2025
Summary
The FDA approved suzetrigine (Journavx), a novel oral, nonopioid pain signal inhibitor for acute pain management. This marks both the first agent in the selective NaV1.8 class and the first new drug approved for acute pain in more than 20 years, representing a significant milestone in the fight against opioid dependency.
Key Changes
- New non-opioid option for acute pain management
- First selective NaV1.8 inhibitor approved
- Alternative to opioid prescriptions for moderate-to-severe pain
Affected Industries
Pharmaceuticals
Healthcare
Pain Management
Source
Key Dates
PublishedJan 30, 2025
Added to RegIntelJan 30, 2025
Related Regulations
SEC Launches Project Crypto Initiative for Digital Asset Framework
SEC · Jul 31, 2025
SEC Permits In-Kind Redemptions for Crypto Asset ETPs
SEC · Jul 29, 2025
SEC Issues Guidance on Crypto Asset Custody by Broker-Dealers
SEC · Dec 17, 2025
SEC Clarifies Liquid Staking Activities Not Securities
SEC · Aug 5, 2025
FDA Approves First At-Home Device for Moderate-to-Severe Depression
FDA · Dec 10, 2025